Vicki L. Davis, Ph.D.
Assistant Professor of Pharmacology

422B Mellon Hall
T 412.396.1168
E davisv@duq.edu

B.S. (Microbiology) --Kansas State University
M.S. (Microbiology) --Kansas State University
Ph.D, (Biochemistry) --University of North Carolina
Post-doctoral research -- National Institute of Environmental Health Sciences Wake Forest University School of Medicine

• PHBMS 355 Human Physiology and Pathology I
• PHBMS 356 Human Physiology and Pathology II
• BMST 427 Biomedical Sciences and Therapeutics

• 1998- 2002 Faculty at Cedars-Sinai Medical Center in Los Angeles, CA in the Center for WomenÕs Health, Department of Obstetrics and Gynecology, and Ophthalmology Research Laboratories

• Estrogen action and signaling;
• Environmental estrogens/endocrine disruptors and breast cancer risk Menopausal therapies and breast cancer risk; Estrogen action in the eye and in cataract development.

• "Breast Cancer Prevention by Inhibition of Estrogen action" California Breast Cancer Research Program: July 1999 Ð March 2002
• "Developmental Effects of Dietary Soy Phytoestrogens" EPA: Aug 1997 - March 2001 (Co-Investigator)
• "Influence of Localized DDT Exposure on Breast Cancer" California Breast Cancer Research Program: July 2000 Ð Dec. 2002
• "Direct Effects of the Pesticide DDT on Breast Cancer" WomenÕs Guild (Private Donation): Dec. 1999 Ð Jan. 2003
• "Black Cohosh and Breast Cancer: Safety and Efficacy" Susan G. Komen Breast Cancer Foundation: Oct. 2000 Ð Sept. 2003
• "Resveratrol for Primary and Metastatic Breast Cancer Prevention" Susan G. Komen Breast Cancer Foundation: June 2003 - May 2005

• Korach KS, Migliaccio S, Davis VL. 1995 Hormonal pharmacology of estrogens and estrogenic compounds. In: Munson P (ed), Principles in Pharmacology. Chapman and Hall, New York, pp 809-826
  Shelby NM, Newbold RR, Tully DB, Chae K, Davis VL. 1996
• Assessing environmental chemicals for estrogenicity using a combination of in vitro and in vivo assays. Environ Health Perspect 104:1296-1300
• Couse JF, Davis VL, Korach KS. 1997 Physiological findings from transgenic mouse models with altered levels of estrogen receptor expression. In: Pavlik EJ (ed), Estrogens, Progestins and their Antagonists. Birkhþuser, Boston, vol 2, pp 69-98
• Couse JF, Davis VL, Hanson RB, Jefferson WN, McLachlan JA, Bullock BC, Newbold RR, Korach KS. 1997 Transgenic mice with aberrant expression of the estrogen receptor demonstrate accelerated onset of uterine tumors after neonatal exposure to diethylstilbestrol. Mol Carcinogenesis 19:236-242
• Davis VL, Couse JF, Korach KS. 1997 Transgenic mouse models with altered expression of the estrogen receptor. In: Sipes IG, McQueen CA, Gandolfi AJ (eds), Comprehensive Toxicology. Pergamon, New York, vol 10, pp 387-394
• Korach KS, Davis VL, Curtis SW, Bocchinfuso WP. 1997 Xenoestrogens and estrogen receptor action. In: Thomas JA, Colby HD (eds), Endocrine Toxicology, 2nd edition. Taylor and Francis, Bristol, PA, pp181-211
• Tully DB, Cox VT, Mumtaz MM, Davis VL, Chapin RE. 2000 Six high-priority organochorine pesticides, either singly or in combination, are nonestrogenic in transfected HeLa cells. Reprod Toxicol 14:95-102
• Davis VL, Chan C-C, Schoen TJ, Chader GJ, Korach KS. 2002 An estrogen receptor repressor induces cataract formation in transgenic mice. Proc Natl Acad Sci USA 99:9427-9432

• Hughes CL, Davis VL, Cline JM. 1997 Dietary soy isoflavones antagonize conjugated equine estrogen-induced proliferation of mammary gland epithelium in ovariectomized female rats. Society for Gynecologic Investigation, Annual meeting, San Diego, CA
• Davis VL, Couse JF, Bullock BC, Newbold RR, Korach KS. 1997 Accelerated onset of uterine tumors in transgenic mice expressing a dominant negative variant of the mouse estrogen receptor after neonatal exposure to diethylstilbestrol. Proceedings of the American Association for Cancer Research, 88th Annual meeting, San Diego, CA; 38:434
• Davis VL, Sweatt AJ, Young RW, Cline JM. Inhibition of estrogen action by an estrogen receptor variant in transgenic mice induces lens opacity. The Association for Research in Vision and Ophthalmology, Annual meeting, Fort Lauderdale, FL; May, 1999.
• Davis VL, Chan CC, Schoen T, Sweatt A, Cline JM, Korach KS, Chader G. Repression of estrogen action through ocular estrogen receptors results in cataracts in ERD3 transgenic mice. US-Japan Cooperative Cataract Research Group Meeting, Kona, Hawaii; Nov., 1999
• Liu G, Blas-Machado U, Duong Q, Lee H, Foster WG, Davis VL, Magoffin DA, Hughes CL. Long-term Exposure to High Lactose Diet Fails to Induce Ovarian Dysfunction in Long-Evans Rats. 33rd Annual Meeting of the Society for the Study of Reproduction. [Abstract # 187], Madison, Wisconsin; July, 2000.
• Davis VL, Shaikh F, Ho A, Hughes CL, Cline JM. Effects of tamoxifen and soy isoflavones on mammary tumor development induced by the neu proto-oncogene. California Breast Cancer Research Program Symposium, Oakland CA; March, 2002.
• Davis VL, Villegas M, Shaikh F, Ho A, Foster WG, Hughes CL. The effects of in utero and lactational exposure to the soy isoflavones, genistein and daidzein, on reproductive development of male and female mice. Abstract #279. 49th annual meeting of the Society for Gynecologic Investigation, Los Angeles, CA; March, 2002.
• Hughes C, Davis VL, Shaikh F, Villegas M, Ho A, Foster W. The effects of in utero and lactational exposure to genistein or daidzein on reproductive development in FVB/N mice and on occurrence of mammary tumors in MMTV-neu transgenic mice. US Environmental Protection Agency Endocrine Disruptors Workshop, Research Triangle Park, October 2002.
• Davis VL, Jayo MJ, Hardy ML, Ho A, Lee H, Shaikh F, Foster WG, Hughes CL. Effects of black cohosh on mammary tumor development and progression in MMTV-neu transgenic mice. Abstract #910. 94th annual meeting of the American Association for Cancer Research, April, 2003.
• Davis VL, Foster WG, Jayo MJ. Ho A, Shaikh F, Lee H, Villegas M, Hughes CL. Influence of locally stored DDT metabolites on mammary cancer development induced by the neu proto-oncogene. Abstract #3441. 94th annual meeting of the American Association for Cancer Research, April, 2003.